Amgen Inc. and MannKind Corporation: SG&A Spending Patterns Compared

A Tale of Two Biotechs: SG&A Spending Trends

In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Amgen Inc. and MannKind Corporation have demonstrated contrasting approaches. From 2014 to 2023, Amgen's SG&A expenses have shown a steady upward trajectory, peaking at approximately $6.2 billion in 2023, a 31% increase from 2014. This reflects Amgen's robust investment in marketing and administrative capabilities to maintain its market leadership.

Conversely, MannKind Corporation's SG&A spending has been more volatile, with a peak in 2015 and a subsequent decline, stabilizing around $94 million in 2023. This represents a modest 19% increase from 2014, indicating a more conservative approach in scaling its operations. These spending patterns highlight the diverse strategies employed by biotech firms in navigating market challenges and opportunities.